MedGenome, an India-focused provider of genetic testing solutions, has raised $55 million in a funding round led by LeapFrog Investments.
Australian VC firm Square Peg Capital has joined a $27 million Series B round for Singapore-based healthcare technology provider Doctor Anywhere.
Zhenge Biotech – a Shanghai-based contract development and manufacturing organization (CDMO) for large molecule drugs – has raised $51 million in Series A funding led by Lyfe Capital.
BGH Capital and Ontario Teachers’ Pension Plan (OTPP) have scrapped plans to acquire New Zealand dentistry chain Abano Healthcare citing material changes caused by COVID-19.
Temasek Holdings has led a $70 million Series C round for Chinese drug developer Abbisko Therapeutics.
Having established itself as a leading player in the renminbi space, China healthcare sector specialist GTJA Investment Group now wants to prove its worth to overseas LPs
Hillhouse Capital has led a $60 million Series B round for China’s Iaso Biotherapeutics via its newly established VC unit GL Ventures.
InnoCare Pharma, a private equity-backed Chinese drug developer focused on treatments for cancer and autoimmune diseases, has raised HK$2.24 billion ($288 million) through a Hong Kong IPO.
RemeGen, a Chinese drug developer, has raised a $100 million round led by Lilly Asia Ventures and Lake Bleu Capital.
Australian healthcare services provider Healius has rejected a A$2.1 billion ($1.4 billion) buyout offer from Partners Group, saying it doesn’t reflect the fundamental value of the company.
China-based biotech developer Harbour BioMed has closed an extended Series B round with a fresh $75 million commitment from a group of VCs. It initially raised $85 million in 2018.
Having raised $595 million for its second healthcare fund, Singapore-headquartered Quadria Capital has a bulky war-chest for investments in fast-growing companies in India and Southeast Asia
University of Tokyo Edge Capital built an unusual bridge between the start-up worlds of Japan and India when backed Tricog's artificial intelligence-enabled healthcare solution
Korea’s SK Telecom has spun out its digital healthcare development unit to form a joint venture (JV) with local private equity firm Newlake Alliance Management.
US-based healthcare investment firm OrbiMed has launched its fourth Asian private equity fund with a view to raising $750 million.
CDH Investments and Shenzhen Capital Group have co-led a $50 million Series B round for GenFleet Therapeutics, a Chinese drug developer.
Motilal Oswal Private Equity (MOPE) has committed INR2.4 billion ($32.4 million) to Molbio Diagnostics, a molecular diagnostics manufacturer that specializes in low-cost diagnosis of tuberculosis and other diseases.
Quadria Capital, a Singapore-headquartered private equity firm that invests in healthcare companies across India and Southeast Asia, has raised $595 million for its second fund.
Eight Roads, an independent investment firm backed by Fidelity International, has appointed pharmaceutical industry veteran Shirish Belapure as a venture partner in its India office.
Tricog, an India-based cardiac analytics firm, has raised $10.5 million in Series B funding from a group of domestic and international VCs.
Chinese health insurance platform Nuanwa Technology has raised a RMB100 million ($14 million) Series A round led by Longfor Capital, a unit of real estate developer Longfor Group.
CBC Group, a China-focused healthcare investor, has raised a $300 million credit fund that will issue financing to companies backed by royalties, revenue interests, and other cash flows.
Qure, an India-based artificial intelligence-enabled medical imaging start-up, has raised $16 million in a Series A round led by Sequoia Capital India and MassMutual Ventures Southeast Asia.
Partners Group has been granted a call option on Chinese conglomerate Jangho Group’s 15.9% stake in Australian healthcare services provider Healius, enabling the private equity firm to make a A$2.1 billion ($1.4 billion) bid for the entire business.